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Can computed crystal energy landscapes help
understand pharmaceutical solids?
Sarah L. Price,*a Doris E. Braunb and Susan M. Reutzel-Edensc
Computational crystal structure prediction (CSP) methods can now be applied to the smaller pharmaceutical
molecules currently in drug development. We review the recent uses of computed crystal energy
landscapes for pharmaceuticals, concentrating on examples where they have been used in collaboration
with industrial-style experimental solid form screening. There is a strong complementarity in aiding
experiment to find and characterise practically important solid forms and understanding the nature of
the solid form landscape.
Introduction
Drug molecules are chosen for their biological properties, and
their solid form properties have to be exploited or worked
around in order to produce the optimum pharmaceutical
product. The drug discovery process usually defines the mole-
cule, and the solid form properties of the molecule are later
optimised in drug development. The investigation of solid form
properties thus has a rather diﬀerent role in pharmaceutical
development than in the design of functional organic materials,
where the molecules themselves are ‘optimised’ to achieve key
physical properties defined by the crystal structure. Nonetheless,
drug development scientists seek to engineer the optimum solid
form properties, such as stability, solubility, dissolution rate,
and process parameters,1–4 through considering single and
multicomponent crystals, particularly salts and cocrystals,
and amorphous forms. The experience of late-appearing, more
stable forms, as in the case of ritonavir5 or rotigotine,6 and the
possibility of ‘‘disappearing polymorphs’’7 means that it
is essential that the drug product is designed knowing the
solubility and other properties of the most stable crystalline
form. Many drug molecules have difficulty in crystallising at all,
and some ‘metastable’ forms may have better properties, such
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as solubility, for developing into the drug product. This has
led to the development of polymorph screening, a survey of
crystallisation conditions designed to identify solid forms of a
drug substance and to determine their crystallisation behaviour.
Solid form screens may encompass hundreds or even thousands
of crystallisation experiments and need to be tailored to the
properties of the individual molecule.8,9 However, drug mole-
cules are typically subjected to solid form screening early in
development, when material quantity and/or purity is often
limited, and there are pressures on timescales to proceed with
biological testing.
Polymorphism, the existence of diﬀerent crystal structures
with the same chemical composition as defined by covalent
bonding and stereochemistry, occurs in at least 50% of mole-
cules that have been subjected to industrial polymorph
screens.8 Multiple solid forms, including salts, cocrystals and
solvates, have been found for 90% of molecules,10 extending
the range of solid form options available for delivering drugs.
The second component in salts and cocrystals is generally
chosen to improve properties. Moreover, the ubiquity of water
in the environment and its presence during processing means
that hydrate formation often cannot be avoided and thus the
properties of those molecular compounds also need to be
established. The (pharmaceutical) solid state may well show
further complexity, leading to problems of classification of poly-
morphism11 with there being structural types with continuous
variation, such as disorder, solid solutions, even salts/cocrystals
with varying proton positions.12
Virtually all pharmaceutical molecules contain flexibly
linked functional groups with multiple, competing hydrogen
bonding and p–p stacking possibilities. The size and flexibility
of the molecules currently under development may be more
challenging than generic small pharmaceuticals studied in
academia. Studies on generic pharmaceuticals such as aspirin,
paracetamol and phenobarbital13 already show considerable
complexity in their polymorphic behaviour, though some
polymorphs may be sufficiently short-lived and difficult to
observe that they could be considered as being only of ‘‘academic’’
interest. Can we assume that the same principles governing the
occurrence of polymorphism and multiple solid forms extend to
larger pharmaceutical molecules in current development? One
recent survey found no statistical correlation with size or degree
of flexibility in the likelihood of a molecule being polymorphic.8
Another survey of all small organic molecules (Mro 1000) in the
European Pharmacopoeia14 showed a decrease in the likelihood
of polymorphism with increasing molecular weight, though this
may simply reflect the difficulty in crystallising larger molecules
as solvent free forms. Every polymorph screen is unique9 and a
matter of observation and experience. The plethora of possible
experiments, which today extends beyond conventional methods
to include heteronuclear screening using a bank of polymers,28
as well as crystallisation in electric29 and ultrasound30 fields,
in laser beams31,32 and under confinement,33 makes it difficult
to have a recipe for complete confidence that all possible
polymorphs are found. This has led to sustained interest in
whether computational modelling can be used to reliably predict
polymorphs, their properties and the experiments needed to
produce seed crystals.23
The fundamental scientific challenge of whether we could
predict crystal structures started in the days when polymorphism
was seen as a rarity, and so the approach of searching for
the most thermodynamically stable crystal structure became
known as crystal structure prediction (CSP).34,35 As interest in
polymorphism increased, it became obvious that some of the
low energy structures, which were local minima in the crystal
energy, corresponded to polymorphs. To date, crystal structure
prediction studies have been performed on many model
drug compounds, and in cases such as aspirin, paracetamol,
carbamazepine and 5-fluorouracil, have anticipated the discovery
of new polymorphs.36 The computational challenge of performing
CSP studies increases non-linearly with the size and flexibility of
the molecule, or the number of independent components in
the crystal. Given the potential usefulness of CSP methods
to the pharmaceutical and speciality chemical industries, the
Cambridge Crystallographic Data Centre has been organising
blind tests of whether those developing crystal structure predic-
tion algorithms can predict crystal structures from the chemical
diagram since 1999.37 The targets have been increasing in
molecular size and diﬃculty reflecting the evolving capabilities
of the leading codes, and the 5th Blind Test26 included mole-
cule XX (Fig. 1), which was seen as approaching the size of the
smaller molecules in drug development. The successful predic-
tion of the crystal structure of XX by two groups38 led to various
industry/academia collaborations on whether CSP methods
would be a useful complement to industrial solid form screening
activities. Indeed, the recent 6th Blind Test27 included a mole-
cule XXIII (Fig. 1), which had been screened in industry, and the
challenge changed to asking participants to submit lists of 100
predicted structures. The account of the 6th Blind Test gives an
overview of the progress and range of computational methods
being developed to tackle the challenges of covering a suﬃcient
range of crystal structures and of scoring the most likely to be
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observed, usually done on relative lattice energies.27 This feature
article covers CSP aided studies on pharmaceutical materials
published since the 5th Blind Test, which have been performed
in collaboration with industrial, or similar, polymorph screening.
Fig. 1 gives the molecular diagrams, along with basic informa-
tion on the number of polymorphs and other solid forms.
What have these CSP studies shown that adds insight to the
experimental results?
Fig. 1 Model pharmaceuticals with combined experimental and computational solid form screening.
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Uses of crystal structure prediction in
pharmaceutical development
Finding the most stable form
The most important output of a polymorph screen is the most
stable form at storage and production conditions, and thus the
main hope is that a CSP study would confirm that this is
known. In the case of strychnine, the only known unsolvated
structure is calculated to be so much more stable than any
other, that this confirms the screening result that strychnine is
not polymorphic (Fig. 2a). The large energy gap, which need not
be calculated to great accuracy, implies that strychnine has
a uniquely favourable way of packing defining the crystal
structure in all three dimensions into a close packed solid.
(The packing index of 76% shows that the molecules are
packing more densely than close-packed spheres at 74%). An
energy gap of this size would not be aﬀected by the inclusion of
temperature eﬀects, and indeed, strychnine does not show
any phase changes upon cooling to 15 K39 or heating before
sublimation, melting or decomposition. Such a large energy
gap is relatively unusual, as many molecules can have a preferred
conformation and strong interactions, such as hydrogen bonding,
defining a strongly preferred ribbon or even layer, but that motif
usually can pack in a range of diﬀerent ways.
A more typical output is shown by 4-aminoquinaldine,40
where there were various competitive low energy structures for
the monohydrate.41 Fig. 2b shows just the crystal energy land-
scape of those structures which were suﬃciently low in energy
to be thermodynamically feasible as polymorphs. In this case,
the calculations predicted a structure which was slightly more
thermodynamically stable and denser than the known struc-
ture. Inspired by this prediction, targeted experiments using
hydrostatic conditions (crystallisation at higher temperatures
under elevated pressure in a hermetically sealed DSC pan) led
to the most stable form of 4-aminoquinaldine monohydrate.
This form had proven very diﬃcult to access experimentally for
kinetic reasons, though it could also be crystallised from
selected solvents at normal pressures if a chemically-related
phase impurity, chloro-4-aminoquinaldine, was present.41
Another case where the calculated crystal energy landscape
predicted that a more stable polymorph existed was creatine,42
a zwitterionic food supplement. The long-known form was a
metastable form but with extremely high kinetic stability (and
an earlier CSP study with too limited a search had concluded43
that this would be the only form). A more recent CSP study
found two thermodynamically competitive structures,42 which
were both found in two independent experimental screens.42,44
Creatine and 4-aminoquinaldine monohydrate represent cases
where careful experimentation has been able to find themost stable
form guided by observation and the CSP generated structures, and
all the energetically most competitive CSP generated structures
have been observed. Whenever there are very thermodynamically
competitive structures, the question naturally arises as to whether
these polymorphs could be found.45
Finding all relevant polymorphs
In many cases, the most stable form is found as the most stable
structure, at least within the uncertainty in the calculation of
the relative energies, and then the question becomes which
of the structures on the crystal energy landscape would seem
likely to be practically important polymorphs, and how might
they be found. This requires looking at the structures to see
similarities between them using various tools such as hydrogen
bonding graph sets46 and other structure comparison tools.47,48
A summary of the output of a CSP study for tazofelone19 is
shown in Fig. 3, which shows that the ‘‘C’’ conformer cannot
pack to give thermodynamically plausible structures, and that
the other types of conformers can only pack with a few types of
Fig. 2 Summary of the CSP study of (a) strychnine (Z0 = 1 and 2) and (b) 4-aminoquinaldine monohydrate (Z0 = 1, adapted from ref. 41). Each point
represents the lattice energy relative to the global minimum and the packing index, PI, of a mechanically stable structure, whose full 3D structure file (.res)
is generated. The points corresponding to the observed structures are highlighted: red – experimental forms known from prior screening, green – form
found guided by the calculations. The structures were generated using CrystalPredictor and all structures shown were refined by periodic electronic
structure calculations (PBE-G06), with the energy cutoff for such refinement being shown on (b), to give their relative lattice energies DElatt.
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hydrogen bonding motif to give structures of suﬃcient thermo-
dynamic stability to be considered as potential polymorphs. It
is this type of classification and comparison with the packing
of the drug molecule and closely related molecules in all their
known forms (as an expansion of, for example, the analysis of
50 carbamazepine-containing crystal structures49) that can provide
the most insight into the crystallisation behaviour required for
drug development.
Suggesting experiments to find new polymorphs
A polymorph that had not been identified in extensive experi-
mental screening of Roche’s CETP inhibitor, dalcetrapib, has
recently been found by crystallisation under pressure, an experi-
ment suggested by the CSP study.24 The crystal energy landscape
showed two structures very close in energy, but denser than the
known stable form, and the unknown structures were calculated
to becomemore stable than the observed polymorph with amodest
increase in pressure. Experiments recrystallising dalcetrapib, either
from solution or the melt in a diamond anvil cell under modest
pressure formed a new polymorph. This matched the predicted
polymorph, except for disorder in the hydrocarbon tail, which
could have been anticipated from the related structures on the
crystal energy landscape.
The known polymorphs of the extensively-screened pharma-
ceutical carbamazepine were, until recently, all based on hydrogen
bonded dimers, although CSP studies suggested that structures
based on a hydrogen bonded catemer were at least thermo-
dynamically competitive. As carbamazepine was often used as a
test case for solid form screening, and indeed the discovery of
Form IV was an early success of polymer heteroscreening,50 the
kinetic accessibility of a catemeric polymorph was debated.51
Eventually the catemeric carbamazepine polymorph Form V was
found by subliming the drug onto a crystal of dihydrocarbamazepine
Form II, which was isostructural with the targeted polymorph.52
This principle of templating by isostructural solid forms
has also been demonstrated for a predicted polymorph of
cyheptamide.53 A CSP predicted benzoic acid:caﬀeine cocrystal
similarly proved to be elusive54 until seeded with a structurally
related molecule, an experiment which was repeated in four
geographically distinct laboratories. These examples show how
having CSP predicted polymorphs can suggest heterogeneous
seeding experiments for cross nucleating polymorph(s), though
far more understanding of heterogeneous nucleation is required
before such tailored experiments can be routinely applied in
pharmaceutical development. Nonetheless, it is well recognised
that impurities can play a major role in determining which
polymorphs can be crystallised7 and hence spiking with possible
reaction product impurities is often included in exhaustive
polymorph screening.
Determination of crystal structure when single crystals cannot
be grown
An important use of the CSP study during a polymorph screen
is to help determine and confirm crystal structures from
experimental powder diﬀraction data, when there are no single
crystals suitable for X-ray diﬀraction. The CSP generated struc-
tures can suggest possible trial structures to be refined against
the experimental data or simply add confidence or detail to the
proposed structure. The calculation of the powder diﬀraction
spectrum from a CSP generated crystal structure with atomic
coordinates is trivial, requiring as input only the wavelength of
radiation. However, the powder pattern is very sensitive to the
cell parameters and the anisotropic thermal expansion of
organic crystals, and CSP generated structures will be in error
typically by a few %, comparable to the neglected thermal
expansion. Methods are being developed to facilitate the auto-
matic use of CSP structures to help solve structures from
powder data.55 There are many reported CSP-aided structure
solutions from powders, ranging from cases where the powder
pattern could not be indexed,56 through suggesting a set of
possible structures that are consistent with pattern indexing, as
discussed later for metastable forms of olanzapine16 and DB7,15
to correcting the proton positions.57 Transmission electron
microscopy and electron diﬀraction have also been used to
detect and characterise new polymorphs and propose their
structures by comparison with CSP generated structures,58
allowing structural characterisation of a polymorphic impurity
that was undetectable by powder X-ray diﬀraction.59
The ability to calculate solid state NMR spectra from
CSP generated structures is increasingly being used for ‘‘NMR
crystallography’’.60,61 One application to pharmaceutical devel-
opment is AZD8329, an 11b-HSD1 inhibitor investigated for use
in the treatment of type 2 diabetes. A structure for AZD8329
Form 4, one of two forms considered to have superior proper-
ties for development, was proposed17 by comparing the experi-
mental proton solid state NMR spectrum with those calculated
from CSP generated structures. This structure for Form 4 was in
excellent agreement with that independently determined from
Fig. 3 Summary of the CSP study of tazofelone adapted from ref. 19.
Each point represents a lattice energy minimum, with structures
categorised by colour to denote the type of conformation (AB extended,
blue; F folded, green; C another low energy conformation, red) and
symbol shape to denote the hydrogen bonding graph set, some of which
are defined in Fig. 4. Open symbols denote the corresponding lattice
energy minima for the experimental structures (labelled on Fig. 4) which
are red for Z0 = 1 structures included in the search and orange for Z0 = 2
structures which are beyond the scope of the search.
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powder X-ray diﬀraction, with the advantage of NMR spectro-
scopy having located the carboxylic acid proton position.
When CSP is being used as an aid to structure determina-
tion, it is possible to restrict the search space using experi-
mental data. For example, a plausible model for the structure of
the antibiotic levofloxacin was proposed after using the crystal
structures of six carboxylic acid salt and hydrate forms to
identify six likely p  p stacked dimer structures, which were
optimised by electronic structure methods and held rigid
during the CSP search.18
The nature of the solid form landscape
The outcome of a CSP study is a set of 3D crystal structures
of the molecule(s) and an estimate of their relative stability.
The interpretation of the results can be straightforward, as in
the crystal energy landscape of strychnine (Fig. 2a), or there
may be a variety of diﬀerent aspects to the crystallisation
behaviour revealed from careful analysis of the structures, as
shown for tazofelone.19 The following examples show how the
diﬀerent crystal energy landscapes can help rationalise the
diﬀerences in crystallisation behaviours that are often an issue
in (drug) development.
Solid form diversity, disorder and why mixtures of polymorphs
sometimes cannot be avoided
In the CSP study of 5-HT2a agonist DB7 (Fig. 1),
15 a metastable
polymorph, Form III, could only be obtained in polycrystalline
form by desolvating the zwitterionic dihydrate.62 The question
was raised as to whether sample-to-sample variability in the
properties of Form III was due to concomitant dehydration to
two closely related polymorphs. The computed crystal energy
landscape found a match to its powder diﬀraction pattern in two
structures, diﬀering only in the propionic acid conformation,
allowing characterisation of this solid form as a single polymorph
with variable sidechain disorder. In this instance, the combined
use of experimental screening and CSP showed a disordered
structure for Form III was inevitable, helping to clarify the
number of forms produced by the solid form screening.15
The neat form of orotic acid is another case where the
anhydrate has diﬀerent levels of order–disorder, this time in
the stacking of a layer structure, depending on how the very
stable hydrate or non-layer dimethylsulfoxide monosolvate are
desolvated. Packing comparisons and chemical shift calcula-
tions for layer structures on the computed crystal energy land-
scape provided models for the stacking faults.63
The problems of diﬀerentiation between polymorphs and
degrees of disorder, and the consequences for the quality
control of crystal properties, is further exemplified by the case
of tazofelone. The original screening of racemic tazofelone had
produced two polymorphs,64 which were based on the same
F:R22(8);C11(10) layer structure (Fig. 4) with diﬀerent stackings
in the third dimension. Revisiting this compound to obtain good
thermodynamic data for calibrating the CSP study19 unexpectedly
produced an alternative stacking as a third polymorph. A particular
concern for ensuring quality control over material properties
was that the large single crystals of each polymorph varied in
melting point! A detailed examination of the hkl raw diﬀraction
images showed some streaking, characteristic of significant
stacking disorder within the crystals which accounts for the
crystal specific properties. The crystal energy landscape (Fig. 4)
had the most stable form as the global minimum, but showed that
there were other ways of stacking the layers that were so close in
energy, that stacking errors or diﬀerent polymorphic domains
(polytypes) within single crystals were probably unavoidable.
The problem of disorder versus concomitant crystallisation is
also apparent for olanzapine, where claims were made for novel
forms that were mixtures of the concomitantly crystallising
metastable polymorphs, Forms II and III. The structure of Form
II was only determined in 2011, when a single crystal suitable for
X-ray diﬀraction analysis could be picked out from a sample of
olanzapine that had failed to co-crystallise with nicotinamide.65
A single crystal suitable for X-ray diﬀraction experiments of Form
III has not yet been found; however, the crystal energy landscape
included a structure that was a suﬃcient match to the Form III
powder pattern to show that it was a diﬀerent stacking of the
Fig. 4 The crystal energy landscape for racemic tazofelone, with the key to
the hydrogen bonding motifs. The figure for F:R22(8);C11(10) is an overlay of
this sheet in the three racemic polymorphs, adapted from ref. 19.
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same molecular layers as Form II.16 This structural model
rationalises why Forms II and III crystallise concomitantly, with
it being practically impossible to generate phase pure samples.
In these cases, the structures on the crystal energy landscape
show how little energy discrimination there is between closely
related structures, thus revealing the possibility of disorder
(conformational or stacking faults) rather than varying propor-
tions of diﬀerent phases. These systems also illustrate the
continuum between closely related polymorphs and varying
degrees of disorder.12 Static disorder can be a thermodynamic
eﬀect: generating all the ordered structures for the 20 molecule
unit cell of the low temperature form of caﬀeine (Form II)
showed that static disorder was favoured by configurational
entropy.66 However, only some of the contributing structures
appeared in the crystal energy landscape for caﬀeine generated
by assuming that all the molecules were related by the space
group symmetry operations. Hence, scientists have to use their
experience to interpret the experiments and crystal energy
landscape to estimate whether closely related calculated struc-
tures are likely to be seen as disorder, or alternatively, are so
similar that they would readily transform to the most stable
structure during the crystallisation process, or not be separate
free energy minima at normal temperatures.
Why are some molecules prolific solvate formers?
A CSP search only generates idealised crystal structures of the
input molecules, and yet can help show the reasons behind
solvate formation. It can show that a molecule cannot pack
densely by itself, and hence there will be a tendency for solvent
to fill the voids in the structure and stabilise it through non-
specific dispersion interactions. This can lead to isostructural
solvates, where diﬀerent solvents or mixtures can be in crystal
structures which are virtually identical in the packing of the
drug molecule. CSP can generate the guest-free framework
of inclusion compounds as a low density structure.67 More
specific solvate formation often occurs for pharmaceuticals
when the hydrogen bonding sites are satisfied by water/solvent
molecules, particularly for drugs where the number and dis-
position of the hydrogen bond donors or acceptors means that
they cannot all be involved in hydrogen bonding.
Many pharmaceuticals are prolific solvate formers, with sulfa-
thiazole having over 100 solvates reported.68 This considerably
complicates the solid form screening output. Pharmaceutical
solvates with solvents which are not suitable for pharmaceutical
processing, as they are not on the GRAS (Generally Recognized
as Safe)69 list, have to be considered in screening because
desolvation20 is a suﬃciently productive method of finding new
forms and may be the only route to a new polymorph.40,42,62,70
Once the first sample is obtained, further samples can be
produced by seeding, either intentionally or unintentionally.
Unlike organic solvates, all possible hydrates have to be identified
and their (de)sorption behaviours extensively studied and char-
acterised because of the diﬃculty of rigorously excluding water
from production processes. Solvates can include multiple
solvents, sometimes in variable ratios, and the distinction between
surface bound water, stoichiometric and non-stoichiometric
hydrates is critical for process design and can be diﬃcult to
establish.62 Labile solvates, where the solvent readily leaves the
crystal when it is removed from the crystallising solution, are
common. This can lead to highly metastable forms if there is a
large kinetic barrier to rearrangement. If no solvates are formed
then this may reflect the ease with which the non-solvated
form crystallises, unless the range of screening experiments is
limited, for example, by the solubility of the crystalline form.
Olanzapine illustrates how the inability of a molecule to
pack well with itself can give rise to a multitude of solid forms,
with over 60 being found in the screen.16 Many of them were
isostructural solvates having diﬀering solvent mixtures between
layers of olanzapine dimers, and the crystal energy landscape
showed that these layers do not stack particularly well to form
an unsolvated crystal. The separation of solvate motifs and
polymorphs is more challenging for the Pfizer oncolytic axitinib
(AG013736), which has 71 solid forms, including 5 polymorphs
containing just the drug molecule.20 A CSP study71 found all of
the axitinib polymorphs, but also showed that there are many
alternative structures that were thermodynamically competitive.
Considerable eﬀorts had already gone into developing targeted
screens20 to circumvent the solvation issues associated with
conventional screening methods. Hence the expense of further
work would only be justified if a clear pathway to crystallising
further non-solvated polymorphs of axitinib could be proposed.
Why do molecules not crystallise at all/form a stable
amorphous phase?
A major complication in pharmaceutical development is when
a molecule fails to crystallise readily, or at all, instead forming
an amorphous phase. The amorphous form, with its greater
solubility, could be an attractive alternative for delivering a
poorly soluble drug if it could be relied upon to not crystallise.
However, experimentally concluding that an amorphous
form is stable is diﬃcult, given the problem of late appearing
polymorphs. There have been informatics methods developed to
seek a statistical probability of a compound not crystallising72,73
that are based on molecular descriptors and assumptions in
classifying the training dataset with respect to the eﬀort that has
gone into trying to crystallise a molecule. The motifs generated
in a CSP study have provided some rationalisation, for example,
why one molecule forms a gel and its isomer crystallises. In this
case, the CSP study predicted the crystalline solid structure and
suggested that the packing preference for the gel former was
one-dimensional hydrogen bonding arranged into tightly coiled
molecular columns which could pack in many ways.74 A CSP
study of salicylsalicylic acid (salsalate), a molecule widely studied
for the stability of its amorphous phase, generated a variety of
energetically competitive structures, based on diﬀerent hydrogen
bonding chains and other motifs.75 The diﬀerent hydrogen-
bonded chains identified in the CSP-computed structures appear
to be seriously detrimental to the molecule’s ability to pack
eﬃciently and stably with the internal hydrogen bonding that is
seen in the experimental crystal structure. The CSP structures
provided a good basis for a model of the amorphous phase;
however, the experimental analysis showed that amorphous
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salsalate is prone to contain oligomeric thermal decomposition
products that could also frustrate crystallisation, and it was
possible to crystallise salsalate more readily than had previously
been suggested.75
Why do structurally similar molecules from the same drug
discovery program have very diﬀerent crystallisation
behaviour?
It might be expected from drug design principles that mole-
cules which are similar enough to bind to the same receptor
would also have similar modes of self-recognition and hence
crystal structures. However, molecules from the same drug
discovery program can pose very diﬀerent challenges when it
comes to progressing solid forms in drug development. A CSP
study investigating this used two 5-HT2a agonists, LY2806920
(B5) and LY2624803 (DB7) (Fig. 1), which contain virtually the
same hydrogen bonding groups and were both under develop-
ment for sleep disorders. B5 readily and reliably crystallises
into just one solid form containing the neutral molecule,
whereas three neat polymorphs, two hydrates, three alcohol
solvates and an amorphous phase are known for DB7.15 The
diﬀerence in the crystallisation behaviour was not a function of
the distribution of the energies of alternative structures. B5 was
able to pack densely with itself, and most of the energetically
competitive structures have the same internal hydrogen bond
as the readily crystallising structure. In contrast, DB7 was
only able to crystallise in structures which had relative low
packing eﬃciencies, and the structures that were competitive
with the most stable form had a variety of intermolecular
hydrogen bonding motifs. The other known polymorphs were
calculated to be relatively unstable, but this is consistent with
these polymorphs being produced by dehydration and salt
disproportionation. This pair of molecules also illustrates the
problem of performing a comparable screening eﬀort: since B5
did not produce any solvates, desolvation studies were not
possible, and its ready crystallisation meant that there was no
amorphous form to be used as input material.
The diﬀerence in crystallisation behaviour between closely
related molecules/isomers is common: structural systematics
comparing structures with minor changes in functional groups
that do not aﬀect the dominant hydrogen bonding motif, can
show significant variations in crystal structure, for example in
5-substituted uracils,76 mandelic acids,77 and 4,40-disubstituted
benzenesulfonamidobenzenes.78 Isomers frequently diﬀer: caﬀeine
has two forms, one statically, the other dynamically disordered,
whereas isocaﬀeine is monomorphic,66 and 2,4-dihydroxybenzoic
acid forms hydrates and its 2,5- isomer does not79 as a consequence
of the stability of the anhydrous form. Crystal structures are clearly
very specific to the individual molecule.
Aiding the design of chiral separation by crystallisation?
Crystallisation is often seen as an ideal process for the separa-
tion of enantiomers, which is required to satisfy regulatory
demands that chiral drugs are administered in an optically
pure form.80 As such, screening and development are generally
directed to just the active enantiomer. The dangers of this
strategy are shown by LY156735, a melatonin agonist, in which
two polymorphs are known, but the most stable form has only
been obtained for the inactive S enantiomer. In fact, had
crystallisation studies not been performed on the inactive
isomer, the screening would give no indication that a more
stable crystal form existed.22 CSP would, however, have alerted
the scientists to this possibility, with the crystal energy land-
scape having both enantiomorphs and the known racemic form
within the top 9 structures, all within 1 kcal mol1 of the
unobserved most stable form.22
Chiral resolution by crystallisation is, of course, only
possible when the opposite enantiomer is rejected during
crystal growth. For tazofelone, the CSP results for enantiopure
crystals (Fig. 5) showed that it cannot pack using the expected
amide–amide N–H  O hydrogen bonding, thus relieving the
need for the additional screening suggested19 by the CCDC
solid form informatics hydrogen bond propensity tool.81 Since
the observed structure had two conformations of the molecule
in the same hydrogen bonding motif (AB:R22(6) Fig. 4) and yet
was significantly more stable than the computer-generated
structures containing just one conformation, there are not
expected to be practically important polymorphs of enantio-
pure tazofelone. However, the crystallisation of enantiopure
tazofelone is not straightforward. The unusual experiment of
seeding a racemic melt with the enantiopure (R or S) crystal
instead results in an isostructural solid solution,82 i.e. the enantio-
pure crystal structure can include a variable proportion ofmolecules
of the other hand. This phenomenon can be explained by the
computed crystal energy landscape19 (Fig. 4) including an
isostructural racemic structure that is more stable than the
enantiomorph, albeit metastable relative to the other known
racemic polymorphs. Since a change in conformation of the
molecule has the same effect on packing as a change in chirality,
recrystallisation of predominantly enantiopure tazofelone will
absorb rather than exclude chiral impurities.
Fig. 5 Summary of the CSP generated enantiopure structures for tazo-
felone adapted from ref. 19. The experimental structure is Z0 = 2 and
hence not found in the Z0 = 1 search (Z0 is the number of independent
molecular conformations in the crystal.) The horizontal line is the cutoﬀ
used for the crystal energy landscape (Fig. 4) that was applied to the CSP
summary (Fig. 3) for crystal structures that could be obtained from a
racemic mixture.
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Is the lack of observed polymorphs in a
screen reliable?
The failure of experimental solid form screens to produce more
than one crystal formmay be due to one form being much more
stable or crystallising much more rapidly than all others. For
true polymorphs, CSP can uniquely suggest whether mono-
morphism is a product of thermodynamics or crystallisation
kinetics. An example where alternative crystal structures were
calculated21 to be only slightly less stable than the only readily
crystallised form is GSK269984B (Fig. 1). In this case, the hypo-
thetical polymorphs had intermolecular hydrogen bonding
compensating for adopting grossly diﬀerent, higher energy
conformations than the observed more stable, internally hydro-
gen bonded conformation.21 Further screening, concentrating
on solvents that would be likely to hydrogen bond to the
drug molecule, produced some metastable solvates with the
expected intermolecular hydrogen bonding, but the same gross
conformation as in the neat form. Thus the question arises as
to whether the fast crystallisation of GSK269984B into its most
stable form could be relied upon to prevent the crystallisation
of the alternative computer generated structures,21 given that
solution NMR showed that a range of other conformations
could exist in solution. In ritonavir, it was the small solution
population of the higher energy conformation that was found
in the most stable polymorph that rationalised its disastrous
late appearance.83,84 The key diﬀerence for GSK269984B is that
the higher energy conformers are calculated to give metastable
polymorphs.
Crizotinib was developed by Pfizer for the treatment of
forms of lung cancer, and extensive polymorph and hydrate
screening similarly found only one crystalline form. A simple CSP
search, based on just four rigid, carefully selected conformers and
the five most common chiral space groups, showed that the
known structure was significantly more stable than any other
generated, rationalising the lack of polymorphs.23 That the known
structure not only had the lowest energy conformation but also
optimal intermolecular interactions was confirmed by a CCDC
solid form informatics ‘‘healthcheck’’.85 It is unusual that there
are no signs of alternative crystal forms in the screening and so
the computational confirmation that there is no compromise
between conformation and intermolecular packing in the struc-
ture, and that it has a uniquely favourable packing defining all
three dimensions, provides valuable reassurance.
Is the number of possible polymorphs
unlimited?
Some intensively studied, highly polymorphic molecules, such
as the precursor of olanzapine known as ROY86 for the red-
orange-yellow spectrum of its many polymorphs, or axitinib,
have a crystal energy landscape71,87 where there are a large
number of thermodynamically competitive but unobserved poly-
morphs. Other families, such as the fenamates and barbiturates,
are also prone to polymorphism, with flufenamic acid until
recently holding the record for the number of solved crystal
structures of diﬀerent polymorphs.88 The crystal energy land-
scapes of the fenamic acids are sensitive to the substitution
pattern.89 In the case of phenobarbital, with 11 known poly-
morphs (though five can only be obtained by isomorphic seeding
with other barbiturates90), four solvates91 and two hydrates,
CSP suggested13 that many further polymorphs are possible,
with Form X being later identified as one of the predicted
structures.92 There are many reasons why CSP often generates
more thermodynamically plausible structures than known poly-
morphs,45 but in these cases more polymorphs may be found
with better techniques for trapping short lived, metastable
forms, or more sophisticated analytical techniques for detecting
phase impurities. This means that new forms are still being
found for heavily studied ‘old’ molecules. In the cases where CSP
studies generate a large number of structures on the crystal
energy landscape, McCrone’s famous statement93 about the
number of polymorphs being determined by the eﬀort expended
on looking for them, continues to hold.
Discussion
What are the advantages of using CSP in developing
pharmaceutical materials?
A CSP study shows what types of crystal packing are particularly
favourable for a specific molecule. Crystal engineering princi-
ples or informatics-based healthchecks85 can quickly show
what may be expected for the functional groups within the
molecule. However, the vastly more computationally expensive
CSP shows the compromises between close packing, conforma-
tional preferences and the diﬀerent types of intermolecular
interactions that determine the crystal structures possible for a
specific molecule. Thus CSP may generate unexpected and
correct crystal structures, as shown in the case of 1-benzyl-1-
H-tetrazole, testing an unusual functional group sometimes
used in pharmaceutical design. The observed crystal structure
was unusual and totally diﬀerent from the tetrazole layer
expected from an analysis of similar crystal structures in the
Cambridge Structural Database.94 Alternatively, a CSP study can
show that a molecule cannot pack with the most favourable
hydrogen bonding motif in a dense fashion with translational
symmetry (e.g. enantiopure tazofelone in Fig. 5).19
The question of ‘‘Are crystal structures predictable?’’27,45,95–97
periodically comes up as CSP methods continue to improve and
this has serious implications for the intellectual property value
of crystal forms. The calculations are closing in on predicting
thermodynamically feasible packings for a growing number of
pharmaceutical compositions; however, the accuracy of the
energy calculations, particularly at relevant processing and
storage temperatures, and the inability to target any low energy
structure on a crystal energy landscape in crystallisation, means
that crystal structure prediction in the truest sense (from
molecular structure to material in hand) is not yet possible.
However, as the examples illustrate, once a CSP study has
determined the set of thermodynamically plausible structures
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for a molecule, then their interpretation in conjunction with
the experimental screening data may generate hypotheses for
the factors affecting its crystallisation and potential further
polymorphs. This can be tested by directed experimentation,
if deemed worthwhile, or used to estimate the risks and
uncertainties involved in the material properties. There is a
long way to go before key properties, such as the solubility,
morphology and mechanical properties of different poly-
morphs at process-relevant temperatures can be estimated
reliably from both observed and computer generated crystal
structures,3 but this could lead to targeted finding of a parti-
cular polymorph for its properties.
What are the challenges in developing CSP as a complement to
solid form screening?
The calculation of crystal energy landscapes to a worthwhile
accuracy is far from routine even for small molecules, as
illustrated by the recent 6th Blind Test of CSP.27 Algorithmic
developments are on-going particularly to deal with flexibility
in the generation of putative crystal structures, but this requires
validation data98 which the pharmaceutical industry is uniquely
suited to provide, as shown by the value of BMS-48804325 for the
development of CrystalPredictor.99 One diﬃculty of CSP is the
vast number of possible structures that need to be considered, as
the study will only generate crystal structures with the input
molecular connectivity and stoichiometry, and the user-specified
range of space groups and number of independent molecules in
the unit cell (Z0). This latter variable is important: it is far more
expensive to cover the search space when there are the additional
variables defining the relative position of two or more indepen-
dent molecules in the asymmetric unit as for cocrystals, salts or
solvates. For a single component search, a Z0 = 2 search should
duplicate the structures found in a Z0 = 1 search, but may
generate others, which may be closely related to a Z0 = 1
structure, or could be intrinsically diﬀerent, for example when
the two molecules are involved in diﬀerent hydrogen bond
interactions, or have diﬀerent conformations (as in enantiopure
tazofelone, Fig. 5). Unfortunately the incidence of Z0 4 1
structures for known polymorphic systems is about 20%, almost
double that for all crystal structures8 within the Cambridge
Structural Database. A further choice is often how much mole-
cular flexibility to consider in the search to ensure that all
conformational polymorphs could be generated.100 The number
of possible local minima in the conformational energy rises very
sharply with the number of flexible torsion angles. This is a
major reason why CSP for pharmaceuticals is so much more
demanding than for other types of molecules with less flexibility.
Molecules comprised of aromatic groups flexibly linked have a
tendency to crystallise in an extended conformation,101 as this
often allows a denser packing stabilised by the dispersion forces,
whereas the more stable isolated molecule conformations with
stronger intramolecular interactions often have awkward shapes
that cannot pack densely. These and many other possible
compromises between the inter- and intra-molecular contribu-
tions to the lattice energy have to be explored in the CSP search.
Once packed into a crystal, further structural optimisation can
only refine the conformation, not cross large energy barriers.
However experimentally there is a similar diﬃculty in transform-
ing between conformational polymorphs, resulting in greater
energy diﬀerences between conformational polymorphs than
for those where the conformations have a common nearest
conformational energy minimum.8 Hence, an extensive CSP
study shows which conformations can generate stable crystal
structures. This contributes to the investigation of the extent to
which the conformational behaviour in solution, and the
mechanisms by which solvent is expelled during nucleation
and growth, determine conformational polymorphism.
All CSP methods that have been successfully applied to
pharmaceuticals use a relatively cheap method of evaluating
the lattice energy in the initial search,99,102 eliminate duplicate
structures and then use more accurate evaluations of the lattice
energy. The most accurate methods are used to determine the
crystal energy landscape, the set of structures that are suﬃ-
ciently thermodynamically stable that they may be experimen-
tally accessible. The most successful methods make extensive
use of electronic structure calculations, either on the molecule
or on the crystal structures. Quantum mechanical calculations
on the molecule can estimate the conformational energy of
the molecule and provide a conformation-dependent, atomic
multipolar model of the charge density for evaluating the
electrostatic component of the intermolecular lattice energy.103
The other contributions to the intermolecular lattice energy
may be evaluated from an empirically fitted transferable model,
usually an atom–atom exp-6 repulsion dispersion model, or a
specifically derived model intermolecular potential. Periodic
electronic structure methods are usually based on density
functional theory (typically the PBE functional) with an essen-
tial correction to model the dispersion interaction, either one
specifically designed for molecular crystals,104 or one of the
many being developed.105,106 The 6th Blind Test showed
how predicting relative energies of crystal structures is really
challenging the development of computational chemistry
methods.27 The successful methods used hundreds of thousands
of CPU hours. The scaling of the cost of the ab initiomethods with
size of molecule and the scaling of the search space with the
number of rotatable torsion angles, means that current methods
could not be scaled to a molecule like ritonavir.5
A fundamental limitation of the current methods is that
they only calculate lattice energies. The ideal crystal energy
landscape for thermodynamically plausible structures would be
a landscape of the free energy at ambient temperature and
pressure. Many lattice energy minima are not free energy
minima and the degree to which the dynamic motions average
over multiple minima depends on the barriers between the
structures. Although free energy can be estimated based on the
harmonic approximation, this does not show when a molecule
may undergo a transition to a dynamically disordered structure, or
one where some functional groups are undergoing large amplitude
motions, such as freely rotating methyl groups. The accurate
determination of the crystal free energy landscape at ambient
temperature and pressure for even the smaller pharmaceuticals
represents a significant challenge to computational modelling.107
Feature Article ChemComm
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
4 
A
pr
il 
20
16
. D
ow
nl
oa
de
d 
on
 1
4/
07
/2
01
6 
13
:0
5:
46
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©The Royal Society of Chemistry 2016 Chem. Commun., 2016, 52, 7065--7077 | 7075
There is a great need for molecular dynamics simulations for
both improved thermodynamics and to start to model the
kinetics involved in crystallisation. CSP is in active develop-
ment for greater accuracy, realism and reduced resource
requirements, as shown by the range of approaches used in
the recent Blind Test of crystal structure prediction.27
Will polymorph prediction ever be a black-box computational
tool? Fundamental understanding of crystallisation for flexible
molecules
Even if we could calculate an accurate free energy landscape of the
possible crystal structures, there is the question of whether we
should expect to be able to find all the really distinct but thermo-
dynamically indistinguishable structures on a crystal energy
landscape as polymorphs, cf. examples of 4-aminoquinaldine
(anhydrate and monohydrate)40,41 and creatine.42 Indeed, it is
questionable whether we should always be able to crystallise
the most stable form, if nucleating the structure is statistically
unlikely77,108 or rearranging the molecules into this structure
from solution or solvated prenucleation clusters is unlikely.
The case of ritonavir,5 where the late appearance of the most
stable form has been linked to only 1% of the molecules in
solution being in the required conformation, or seeding by an
impurity, illustrates the need for both CSP and a better under-
standing of the competition in the kinetics of nucleation and
growth between polymorphs.
As with smaller molecules, the challenges in interpreting the
computed crystal energy landscape are to predict which struc-
tures are going to be practically important polymorphs, suggest
experiments to find them, and design suitable processing
methods.109 In addition, for larger molecules, with increasing
flexibility,110 there can be the possibility of trapping highly
metastable polymorphs, or diﬃculty in crystallising the mole-
cule at all. Larger molecules are more liable to thermal decom-
position, and may not have suﬃcient solubility in a wide range
of solvents, thus reducing the scope of conventional screening
methods. It can be diﬃcult to ensure that a solution is free of
nuclei of the input material.111 On the other hand, a better
understanding of heterogeneous nucleation will improve the
ability to design heteronuclear seeds and experiments to gen-
erate computationally predicted polymorphs.53
Hence, although the crystal energy landscape currently tends
to over-predict polymorphism, modern solid form screening
methods probably underestimate the range of polymorphs.8
There are inadequacies in the methods of calculating which
structures are thermodynamically plausible as polymorphs, and
a lack of understanding of how the kinetic factors of nucleation
and growth can be varied by heterogeneous nucleation and the
extent to which we can vary the conditions to find new forms.
At least, if a structure has been shown by reliable CSP to be
thermodynamically plausible, the question is what experiment
might nucleate that form for the first time or at least help
determine that it is experimentally unreachable, given the
target structure. This is a significant advance on empirical
polymorph screening.
Conclusions
Recent advances in our ability to calculate worthwhile crystal
energy landscapes for larger molecules have enabled them to
be combined with industrial quality experimental solid form
screening results. This has shown that the crystal energy
landscape gives a useful framework for understanding the
complexity of solid form landscapes for small drug molecules,
and has the potential to help direct eﬀective experimentation.
There is no routine ‘‘black-box’’ recipe for either computational
(CSP) or experimental polymorph screening, with both needing
adapting to the properties of the individual molecule and the
aim of the study. However, the successes of computed crystal
energy landscapes for motivating the finding of thermodyna-
mically stable polymorphs, helping to structurally characterise
new polymorphs, anticipating disorder and generally helping to
rationalise the diversity of the solid form landscapes, shows
that such methods can form a valuable complement to solid
form screening.
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